Skip to main content
    E

    Elutia Inc. (ELUT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.82
    +0.00 (+0.35%)

    Market Cap: $36.41M

    Last updated: Nov 17, 2026 at 10:51 AM ET

    Elutia Inc. (ELUT) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Elutia (ELUT) trades at 0.8x trailing earnings and 10.9x sales. Its P/S of 10.9x is above its 5-year median of 3.0x.

    Current Multiples

    MultipleValue
    P/E (trailing)0.8x
    Forward P/EN/A
    Price to sales10.9x
    Price to book2.4x
    PEGN/A
    FCF yield-139.0%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S10.9x3.0xN/A
    Medians of month-end values through Oct 2026: 59 months (5-year).

    Valuation History

    Over the 5 of the 6 year ends shown that have a P/S, its P/S ranged from 1.4x in 2021 to 7.4x in 2025. 2025 was the highest of those years.

    Year endPriceP/EP/SP/B
    2025$0.690.7x7.4x1.2x
    2024$3.74N/A6.4xN/A
    2023$2.16N/A1.5xN/A
    2022$4.25N/A2.4xN/A
    2021$6.30N/A1.4x8.2x
    2020$13.63N/AN/AN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ELUT

    Is ELUT stock overvalued?

    GNG's valuation label for ELUT is Overvalued.

    What is ELUT's price to sales ratio?

    Elutia has a price to sales ratio of 10.9x.